
|Videos|January 13, 2022
Pharmacist Medication Insights: Somapacitan (Sogroya) for Growth Hormone Deficiency
Author(s)Saro Arakelians, PharmD
Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
Advertisement
Somapacitan (Sogroya; Novo Nordisk) injection is approved for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
The human growth hormone analogue is administered via subcutaneous injection once weekly.
Somapacitan acts similarly to human growth hormone. After injection, the drug attaches to a protein in the blood called albumin, which allows it remain in the body for longer. This enables weekly administration of Sogroya, which is favorable to the daily dosing of other growth hormone replacement therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma
2
What Does the FDA Advisory Committee’s Vote on 7 Peptides Mean for Pharmacy Practice?
3
Beyond Off-Label: How Auvelity's Approval Changes Agitation Management in Alzheimer Disease
4
FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening
5











































































































